Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2293-2295

  Alffenaar, J W C ^a   De Vries, P M ^a   Luijckx, G J ^a   Van Soolingen, D ^b   Van Der Werf, T S ^a   Van Altena, R ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; OMEPRAZOLE; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; CASE REPORT; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG PENETRATION; HUMAN; LETTER; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOUS MENINGITIS;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; DRUG MONITORING; HUMANS; MALE; QUINOLINES; TUBERCULOSIS, MENINGEAL;

EID: 44449104090     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01637-07     Document Type: Letter

References (14)

1. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
2. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
3. Codecasa, L. R., G. Ferrara, M. Ferrarese, M. A. Morandi, V. Penati, C. Lacchini, P. Vaccarino, and G. B. Migliori. 2006. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir. Med. 100:1566-1572.
4. Nijland, H. M. J., R. Ruslami, A. J. Suroto, D. M. Burger, B. Alisjahbana, R. van Crevel, and R. E. Aarnoutse. 2007. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis. 45: 1001-1007.
5. Ostergaard, C., T. K. Sorensen, J. D. Knudsen, and N. Frimodt-Moller. 1998. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob. Agents Chemother. 42:1706-1712.
6. Rodríguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
7. Rodriguez-Cerrato, V., C. C. McCoig, I. C. Michelow, F. Ghaffar, H. S. Jafri, R. D. Hardy, C. Patel, K. Olsen, and G. H. McCracken, Jr. 2001. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob. Agents Chemother. 45:3092-3097.
8. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, Sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
9. Stass, H., and A. Dalhoff. 1997. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J. Chromatogr. B Biomed. Sci. Appl. 702:163-174.
10. Stass, H., D. Kubitza, and U. Schuhly. 2001. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin. Pharmacokinet. 40(Suppl. 1):1-9.
11. Valerio, G., P. Bracciale, V. Manisco, M. Quitadamo, G. Legari, and S. Bellanova. 2003. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J. Chemother. 15:66-70.
12. van Klingeren, B., M. Dessens-Kroon, T. van der Laan, K. Kremer, and D. van Soolingen. 2007. Drug susceptibility testing of Mycobacterium tubercu losis complex by use of a high-throughput, reproducible, absolute concentration method. J. Clin. Microbiol. 45:2662-2668.
13. Weiner, M., W. Burman, C. C. Luo, C. A. Peloquin, M. Engle, S. Goldberg, V. Agarwal, and A. Vernon. 2007. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 51:2861-2866.
14. Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother. 46:1875-1879.